Form 4: United Therapeutics EVP Exercises, Sells Shares

United Therapeutics' EVP & General Counsel, Paul A. Mahon, exercised stock options and sold 11,000 shares of common stock under a pre-arranged 10b5-1 plan.

Summary

• Paul A. Mahon, Executive Vice President and General Counsel of United Therapeutics Corp, reported transactions on December 24, 2025.
• The transactions involved the exercise of 11,000 stock options at an exercise price of $146.03 per share.
• Concurrently, 11,000 shares of common stock were sold in multiple transactions.
• The sale prices for the common stock ranged from $509.2166 to $516.06 per share.
• These transactions were conducted pursuant to a pre-arranged Rule 10b5-1 plan, which was entered into by the reporting person on December 24, 2024.
• Following these reported transactions, Mahon beneficially owns 36,781 shares of common stock directly and 9,250 derivative securities (stock options).

Sentiment

Score: 5

Explanation: The filing reports a routine insider transaction (exercise of options and sale of shares) conducted under a pre-arranged 10b5-1 plan, which is a common practice for executives managing their equity compensation. It does not contain information that would significantly alter the company's fundamental outlook.

Positives

• The executive realized a significant profit from exercising options and selling shares, indicating personal financial benefit.
• The transactions were conducted under a pre-arranged 10b5-1 plan, which suggests a planned liquidity event rather than a reaction to new, negative information.

Negatives

• Insider selling, even under a 10b5-1 plan, can sometimes be perceived by the market as a lack of confidence, though this is often mitigated by the pre-planned nature.

Future Outlook

This Form 4 filing does not contain any forward-looking statements or guidance regarding the company's future performance or outlook.

Industry Context

This insider transaction is a routine event for executives in publicly traded companies, particularly in the biotechnology sector where equity compensation is common. It reflects an individual's financial planning rather than a broader industry trend or competitive action.

Stakeholder Impact

• Shareholders: May observe a routine insider sale, which is generally less impactful when conducted under a 10b5-1 plan, but could still lead to minor short-term sentiment shifts.

Key Dates

Keywords

United Therapeutics, UTHR, Insider Trading, Form 4, Stock Options, 10b5-1 Plan, Executive Compensation, Biotechnology